JW Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
JW Pharmaceutical has a total shareholder equity of ₩275.3B and total debt of ₩124.2B, which brings its debt-to-equity ratio to 45.1%. Its total assets and total liabilities are ₩657.4B and ₩382.2B respectively. JW Pharmaceutical's EBIT is ₩102.4B making its interest coverage ratio 15.1. It has cash and short-term investments of ₩108.8B.
Key information
45.1%
Debt to equity ratio
₩124.17b
Debt
Interest coverage ratio | 15.1x |
Cash | ₩108.77b |
Equity | ₩275.26b |
Total liabilities | ₩382.19b |
Total assets | ₩657.45b |
Recent financial health updates
Recent updates
JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality
Mar 21Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?
Apr 08How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?
Mar 13Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.
Jan 19Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend
Dec 24Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?
Nov 30Financial Position Analysis
Short Term Liabilities: A001060's short term assets (₩389.2B) exceed its short term liabilities (₩295.5B).
Long Term Liabilities: A001060's short term assets (₩389.2B) exceed its long term liabilities (₩86.7B).
Debt to Equity History and Analysis
Debt Level: A001060's net debt to equity ratio (5.6%) is considered satisfactory.
Reducing Debt: A001060's debt to equity ratio has reduced from 80.3% to 45.1% over the past 5 years.
Debt Coverage: A001060's debt is well covered by operating cash flow (98.6%).
Interest Coverage: A001060's interest payments on its debt are well covered by EBIT (15.1x coverage).